Displaying 1 - 20 of 54
| Active Ingredient | ACTINOMYCIN D |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ANASTROZOLE |
| Therapeutic Class | ANTINEOPLASTICS - Aromatase Inhibitor |
| Indications | Advanced or locally advanced breast cancer, adjuvant treatment in hormone receptor-positive early breast cancer in postmenopausal women. |
| Caution | Gastrointestinal disturbances, hot flushes, dizziness, drowsiness, headache, rash, hair thinning, vaginal dryness or bleeding, myalgia, arthralgia, carpal tunnel syndrome, and bone pain and/or More ... |
| Dose Range | Adult: 1 mg once daily with or without food. |
| Drug Interactions |
Estrogen-containing Therapies Tamoxifen |
| Pregnancy | Avoid in pregnancy. This drug can cause fetal toxicity when administered to preg More ... |
| Breast Feeding | Avoid. |
| Active Ingredient | ANTINEOPLASTICS |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | AZATHIOPRINE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Usually as an adjunct to corticosteroids, in autoimmune disorders, e.g. SLE and rheumatoid arthritis. C.f. prescribing in liver and renal disease p. 11; 23. |
| Caution | leukopenia, infection,abdominal pain, alopecia, diarrhea, fever, rash, bone marrow suppression, myalgia |
| Dose Range | 1-3mg/kg daily , usually 100-200mg daily . Take with food. |
| Drug Interactions | |
| Pregnancy | Azathioprine can cause fetal harm when administered to a pregnant woman.The manu More ... |
| Breast Feeding | Breast feeding has not been recommended in azathioprine therapy because of the p More ... |
| Active Ingredient | BEVACIZUMAB |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | BICALUTAMIDE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Bicalutamide is indicated either alone or as adjuvant to radical prostatectomy or radiotherapy in patients with locally advanced prostate cancer at high risk for disease progression. |
| Caution | Consider periodic liver function tests. Constipation, dyspepsia, flatulence, pruritus, asthenia, alopecia, jaundice, dry skin, hot flashes, gynaecomastia and/or breast pain and photosensitiv More ... |
| Dose Range |
50mg once daily in conjunction with a gonadotropin-releasing hormone (GnRH) analog. 150 mg once a day as monotherapy |
| Drug Interactions |
Bicalutamide is an inhibitor of CYP 3A4, with lesser inhibitory effects on CYP 2C9, 2C19 and 2D6 activity. Caution should be exercised with the co-administration of bicalutamide with compounds such a More ... |
| Pregnancy | Bicalutamide is contraindicated in females and should not be used |
| Breast Feeding | Bicalutamide is contraindicated in females and should not be used during breast- More ... |
| Active Ingredient | BLEOMYCIN SULPHATE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Squamous cell carcinomas. |
| Caution | Extravasation, thromboembolism, nausea, vomiting,stomatitis, fever and chills, alopecia, pulmonary fibrosis. |
| Dose Range |
i.v. i.m: 15 000 IU.3 times a week, or 30 000 IU. Twice a week in combination regimens. This may be repeated, at 3 to 4 weeks intervals, up to a total cumulative dose of 500 000 IU. Dose and total cumulative dose should be reduced in those ov |
| Drug Interactions | |
| Pregnancy | Bleomycin sulfate can cause fetal toxicity when administered to pregnant women. More ... |
| Breast Feeding | Discontinue breastfeeding. |
| Active Ingredient | BUSULPHAN |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Chronic myeloid leukaemia. |
| Caution | Leukopenia, thrombocytopenia, anaemia, amenorrhoea, (occasional), skin hyperpigmentation (occasional), gynecomastia (occasional) Adisonian - like wasting syndrome, pulmonary fibrosis (rare More ... |
| Dose Range |
60 micrograms/kg daily , with a usual maximum single daily dose of 4 mg. Maintenance: 0.5-2mg daily . |
| Drug Interactions | |
| Pregnancy | Busulfan may cause fetal harm when administered to pregnant women, but potential More ... |
| Breast Feeding | Discontinue breast-feeding. |
| Active Ingredient | CAPECITABINE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Metastatic colorectal cancer, locally advanced or metastatic breast cancer after failure of anthracycline-containing chemotherapy. |
| Caution | Diarrhoea (which may be severe), nausea and vomiting, abdominal pain, stomatitis. |
| Dose Range | Initial oral dose 1.25 g/m2 given twice daily . Doses are given for 14 days, followed by a 7-day rest period. |
| Drug Interactions | |
| Pregnancy | Capecitabine may cause fetal harm when administered to pregnant women. Capecitab More ... |
| Breast Feeding | Because of the potential for serious adverse reactions to capecitabine in nursin More ... |
| Active Ingredient | CARBOPLATIN |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Advanced ovarian cancers and of small-cell lung cancer. |
| Caution | As for cisplatin. Myelosuppression may be more severe than cisplatin and prolonged in patients with impaired renal function. |
| Dose Range | Adult: dose of carboplatin is determined according to renal function rather than body surface area. |
| Drug Interactions | |
| Pregnancy | Carboplatin can cause fetal toxicity when administered to pregnant women, but po More ... |
| Breast Feeding | Because of the potential for serious adverse reactions to carboplatin in nursing More ... |
| Active Ingredient | CHLORAMBUCIL |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Chronic lymphocytic leukemia, lymphomas |
| Caution | Anorexia, nausea, leukop enia, throm-bocytopenia, anaemia. Drink 6-8 glasses of liquid everyday.Avoid aspirin or medication containing aspirin. |
| Dose Range | 0.1-0.2mg/kg/day (usually 4-10mg once daily ) for 3-4 weeks. |
| Drug Interactions | |
| Pregnancy | Chlorambucil can cause fetal harm when administered to pregnant women, but poten More ... |
| Breast Feeding | Discontinue breast-feeding. |
| Active Ingredient | CISPLATIN |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Treatment of testicular, lung, cervical, bladder, head and neck, and ovarian cancer. |
| Caution | Alop ecia, bone-marrow suppression,extravasation, hyperuricaemia, hypomagnesaemia, myelosuppression, nephrotoxicity severe nausea, severe vomiting. |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | Cisplatin may cause fetal harm when administered to a pregnant woman but potenti More ... |
| Breast Feeding | Cisplatin is distributed into milk. Nursing should be discontinued to avoid the More ... |
| Active Ingredient | CYCLOPHOSPHAMIDE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Non-Hodgkin’s lymphomas. |
| Caution | High fluid intake will help to prevent haemorrhagic cystitis (3-4 litres/day ). C.f. prescribing in renal disease p. 27. |
| Dose Range | Low-dose: 2-6 mg/kg weekly as a single i.v. dose/ in divided oral doses; moderate-dose:10-15 mg/kg weekly as a single i.v. dose; High-dose: 20-40 mg/kg as a single i.v. dose every 10-20 days, depending on the disease being treated, condi |
| Drug Interactions | |
| Pregnancy | Cyclophosphamide can cause fetal toxicity when administered to pregnant women, b More ... |
| Breast Feeding | Discontinue breast-feeding during and for 36 hours after stopping treatment. |
| Active Ingredient | CYCLOSPORIN |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Prophylaxis of graft rejection in Organ and tissue transplantation. |
| Caution | Abdominal pain; anorexia; diarrhoea; fatigue; gingival hyperplasia; headache; hepatic dysfunction. Renal dysfunction (renal structural changes on long-term administration). |
| Dose Range |
Ciclosp orin is 10 to 15 mg/kg daily , beginning 4 to 12 hours before transp lantation, and continued for 1 to 2 weeks. maintenance 2-6 mg/kg daily, reduce dose gradually to maintenance |
| Drug Interactions | |
| Pregnancy | Cyclosporin crosses the placenta; manufacturer advises to avoid unless potential More ... |
| Breast Feeding | Avoid breastfeeding during cyclosporin therapy. |
| Active Ingredient | CYPROTERONE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Advanced prostatic carcinoma. |
| Caution |
Impotence, inhibition of spermatogenesis, headache, gynecomastia, galactorrhea, weight gain, lipid abnormalities, gastrointestinal disturbances and anemia. Several cases of hep ato More ... |
| Dose Range | Palliative treatment: 200- 300 mg daily in 2 or 3 divided doses after meals. S uppression of disease flare: 100 mg twice daily used alone for 5 to 7 day s, then with a gonadorelin analogue for 3 to 4 weeks. |
| Drug Interactions | |
| Pregnancy | Use of cyproterone during pregnancy might carry a risk of feminisation of a male More ... |
| Breast Feeding |
| Active Ingredient | CYTARABINE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Induction of remission of acute myeloblastic leukaemia. |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | Cytarabine can cause fetal toxicity when administered to pregnant women, but pot More ... |
| Breast Feeding | Discontinue breast-feeding. |
| Active Ingredient | DACARBAZINE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Metastatic melanoma. |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | Dacarbazine should be used during pregnancy only when the potential benefits jus More ... |
| Breast Feeding | Discontinue breast-feeding. |
| Active Ingredient | DAUNORUBICIN |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Induction of remission of acute leukaemias. |
| Caution | Dose related myelosuppression, cardiotoxicity, alopecia, urine discoloration; extravasation. |
| Dose Range | 40 - 60 mg/m2 on alternate days for a course of up to 3 injections. |
| Drug Interactions | |
| Pregnancy | Daunorubicin may cause fetal harm when administered to a pregnant woman. Animal More ... |
| Breast Feeding | Discontinue breastfeeding. |
| Active Ingredient | DOCETAXEL |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Use as neoadjuvent with metastatic breast cancer. |
| Caution | As for Paclitaxel. |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | Docetaxel may cause fetal harm when administered to pregnant women, but potentia More ... |
| Breast Feeding | It is not known whether docetaxel is distributed into milk. |
| Active Ingredient | DOXORUBICIN |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Hodgkin's disease, non-Hodgkin's lymphomas, acute leukaemias. |
| Caution | Myelosuppression, reversible, alopecia, nausea, vomiting |
| Dose Range | 60-75mg/M 2 i.v. as a single injection every 3 or 4 weeks; or 1.2-2.4 mg/kg once every 3 weeks. |
| Drug Interactions | |
| Pregnancy | Doxorubicin can cause fetal toxicity when administered to pregnant women, but po More ... |
| Breast Feeding | Not recommended. |